<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7162773\results\search\drug\results.xml">
  <result pre="experts is that neuraminidase inhibitors (oseltamivir, peramivir, zanamivir, etc) and" exact="ganciclovir" post="are not generally recommended. Routine prophylactic antibiotics, especially combined"/>
  <result pre="in the guidelines of the NHC Medication instruction Alpha-interferon Lopinavir/ritonavir" exact="Ribavirin" post="Chloroquine Arbidol Recommended dosage and course 5 million units"/>
  <result pre="the guidelines of the NHC Medication instruction Alpha-interferon Lopinavir/ritonavir Ribavirin" exact="Chloroquine" post="Arbidol Recommended dosage and course 5 million units or"/>
  <result pre="than in the lopinavir/ritonavir group.43 In early inÂ vitro studies," exact="chloroquine" post="and hydroxychloroquine were found to inhibit SARS-CoV-2 infection efficiently,40,44"/>
  <result pre="the lopinavir/ritonavir group.43 In early inÂ vitro studies, chloroquine and" exact="hydroxychloroquine" post="were found to inhibit SARS-CoV-2 infection efficiently,40,44 and several"/>
  <result pre="conducted in China to evaluate the efficacy and safety of" exact="chloroquine" post="and hydroxychloroquine. Gao etÂ al. summarized that compared with"/>
  <result pre="Gao etÂ al. summarized that compared with the control treatment," exact="chloroquine" post="phosphate was effective in inhibiting the exacerbation of pneumonia,"/>
  <result pre="conversion, and shortening the disease course.45 The expert consensus on" exact="chloroquine" post="phosphate recommends 500 mg twice daily for 10 days"/>
  <result pre="10 days for patients diagnosed with COVID-19. Adverse effects of" exact="chloroquine" post="and hydroxychloroquine must be carefully monitored.46 Zhou etÂ al."/>
  <result pre="for patients diagnosed with COVID-19. Adverse effects of chloroquine and" exact="hydroxychloroquine" post="must be carefully monitored.46 Zhou etÂ al. proposed that"/>
  <result pre="hydroxychloroquine must be carefully monitored.46 Zhou etÂ al. proposed that" exact="hydroxychloroquine" post="could serve as a better therapeutic agent than chloroquine,"/>
  <result pre="etÂ al. used physiologically based pharmacokinetics models and found that" exact="hydroxychloroquine" post="was more potent than chloroquine at inhibiting SARS-CoV-2 inÂ"/>
  <result pre="pharmacokinetics models and found that hydroxychloroquine was more potent than" exact="chloroquine" post="at inhibiting SARS-CoV-2 inÂ vitro. They recommended 400 mg"/>
  <result pre="chloroquine at inhibiting SARS-CoV-2 inÂ vitro. They recommended 400 mg" exact="hydroxychloroquine" post="sulfate twice daily for 1 day, followed by 200"/>
  <result pre="to treat SARS-CoV-2 infection.48 The efficacy and safety data of" exact="chloroquine" post="or hydroxychloroquine from high-quality clinical trials are urgently needed."/>
  <result pre="SARS-CoV-2 infection.48 The efficacy and safety data of chloroquine or" exact="hydroxychloroquine" post="from high-quality clinical trials are urgently needed. Glucocorticoid therapy"/>
  <result pre="of corticosteroids at low to moderate dose (â‰¤ 0.5-1 mg/kg/d" exact="methylprednisolone" post="or equivalent) for critically ill patients with COVID-19.50 According"/>
  <result pre="vital signs (blood pressure and heart rate), laboratory tests including" exact="creatine" post="kinase, lactate dehydrogenase, high-sensitivity cardiac Troponin I, creatine kinase"/>
  <result pre="tests including creatine kinase, lactate dehydrogenase, high-sensitivity cardiac Troponin I," exact="creatine" post="kinase MB, B-type natriuretic peptide (BNP) and N-terminal proBNP,"/>
  <result pre="(BNP) and N-terminal proBNP, and electrocardiography. Antiviral drugs, such as" exact="ribavirin" post="and lopinavir/ritonavir, have been widely used in cardiac patients,"/>
  <result pre="adults hospitalized with severe Covid-19N Engl J Med38220201787179932187464 40WangM.CaoR.ZhangL.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) inÂ"/>
  <result pre="is effective in inhibiting SARS-CoV-2 infection inÂ vitroCell Discov620201632194981 45GaoJ.TianZ.YangX.Breakthrough:" exact="chloroquine" post="phosphate has shown apparent efficacy in treatment of COVID-19"/>
  <result pre="of Guangdong Province and Health Commission of Guangdong Province for" exact="Chloroquine" post="in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus"/>
  <result pre="in the Treatment of Novel Coronavirus Pneumonia. [Expert consensus on" exact="chloroquine" post="phosphate for the treatment of novel coronavirus pneumonia]Zhonghua Jie"/>
  <result pre="Tong Q. COVID-19: a recommendation to examine the effect of" exact="hydroxychloroquine" post="in preventing infection and progression [e-pub before print]. J"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 </snippets>
</snippetsTree>
